Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2026
Reporting Period: Event-based report for January 14, 2026
ImmunityBio, Inc., a Delaware corporation headquartered in San Diego, California, filed this report to disclose regulatory approvals granted by the Saudi Food and Drug Authority (SFDA).
Key Financial Metrics
This filing is an event-based report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the receipt of accelerated regulatory approvals in Saudi Arabia for the Company's product, ANKTIVA, on two indications:
- Metastatic Non-Small Cell Lung Cancer (NSCLC): Approved for use in combination with immune checkpoint inhibitors for adult patients whose disease has progressed following standard-of-care therapy.
- Non-Muscle Invasive Bladder Cancer (NMIBC): Approved for use in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive carcinoma in situ, with or without papillary disease.
Guidance, Outlook, and Risks
Management Commentary: The filing references press releases (Exhibits 99.1 and 99.2) detailing the approvals but does not include forward-looking guidance, financial outlook, or specific management commentary within the body of the 8-K text provided.
Risks and Contingencies: The filing explicitly states that the information in Item 8.01 and the attached exhibits shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section, except as expressly set forth by specific reference. No specific risks or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Verify the full text of the press releases attached as Exhibit 99.1 and Exhibit 99.2 for specific commercial terms or launch timelines in Saudi Arabia.
- Confirm the commercial significance of the Saudi market relative to ImmunityBio's global revenue strategy.
- Review subsequent filings (e.g., 10-Q or 10-K) for financial impact analysis of these approvals.
- Check for any pending regulatory actions in other major jurisdictions (e.g., FDA, EMA) for the same indications.